This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of amantadine
PDMED_AMANTADINE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
714 |
4. Check minimum number of events
Min. number of events
3
|
714 |
5. Include endpointsNone |
714 |
6. Filter based on genotype QC (FinnGen only) |
633 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of amantadine
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 633 | 411 | 222 |
| Unadjusted period prevalence (%) | 0.13 | 0.15 | 0.10 |
| Median age at first event (years) | 52.96 | 48.46 | 61.29 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 647
- Matched controls
- 6470
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N86
ICPC
Multiple sclerosis
182.7
307.7
164
12
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
42.5
307.7
271
108
N04BB01
ATC
amantadine; oral
+∞
307.7
647
29
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
142.2
307.7
191
19
109
Kela drug reimbursment
Multiple sclerosis
157.1
307.7
219
21
G35
ICD-10 Finland
Multiple sclerosis
137.3
307.7
272
34
G20
ICD-10 Finland
Parkinson disease
54.4
307.7
264
81
N04BD01
ATC
selegiline; oral
109.1
307.7
203
27
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
59.9
307.7
267
75
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
109.5
307.7
176
22
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
113.6
290.1
149
17
N04BD02
ATC
rasagiline; oral
134.4
289.8
146
14
L03AB07
ATC
interferon beta-1a; parenteral
146.2
258.2
129
11
193
Kela drug reimbursment
Rasagiline
137.8
244.8
123
11
N87
ICPC
Parkinsonism
51.3
234.1
138
34
N04BC04
ATC
ropinirole; oral
88.2
207.6
110
15
L03AX13
ATC
glatiramer acetate; parenteral
120.9
200.3
102
10
M03BX01
ATC
baclofen; systemic
27.5
166.4
118
52
N04BC05
ATC
pramipexole; oral
10.0
150.1
210
298
N03AE01
ATC
clonazepam; systemic
11.8
140.9
163
179
H46
ICD-10 Finland
Optic neuritis
40.7
133.0
82
23
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
58.3
120.1
68
13
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
8.0
113.0
184
305
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
62.4
102.0
57
10
G04BD12
ATC
mirabegron; oral
5.2
76.4
200
509
L03AB08
ATC
interferon beta-1b; parenteral
177.0
75.9
78
5
G04BD09
ATC
trospium; oral
12.5
75.7
78
70
N04BX02
ATC
entacapone; oral
141.1
71.6
75
6
XA800
NOMESCO Finland
Neuropsychological investigation
8.3
67.0
95
131
G04BD04
ATC
oxybutynin; oral, transdermal
6.6
67.0
122
221
XKD06
NOMESCO Finland
Physiologic investigation of micturition
9.2
61.6
79
96
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
14.4
61.2
57
43
N03AX12
ATC
[U] gabapentin; oral
4.0
56.2
214
709
164
Kela drug reimbursment
Fingolimod
203.9
54.9
56
*
N06BA07
ATC
modafinil; oral
127.2
54.8
58
5
SPAT1229
SPAT
Assessment of need for aid
5.1
48.1
114
260
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
20.6
47.9
37
19
L04AA27
ATC
[U] fingolimod
252.9
46.6
47
*
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
18.3
46.6
38
22
353
Kela drug reimbursment
Cladribine and fingolimod
168.6
45.4
47
*
N04AA02
ATC
biperiden; systemic
10.8
44.8
50
50
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
8.7
44.6
59
74
G04BD07
ATC
tolterodine; oral
5.7
44.2
89
175
N04BC09
ATC
rotigotine; transdermal
67.5
43.9
50
8
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
235.6
43.5
44
*
SPAT1215
SPAT
Assessment of need for medical rehabilitation
7.1
41.6
66
102
L04AA31
ATC
[U] teriflunomide
117.8
41.3
44
*
XKC03
NOMESCO Finland
Water cystometry
7.3
41.0
63
94
UKC02
NOMESCO Finland
Cystoscopy
3.4
36.7
167
604
J01EA01
ATC
trimethoprim; systemic
2.9
36.2
261
1227
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
45.9
35.4
43
10
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
100.8
35.1
38
*
G04BD08
ATC
solifenacin; oral
4.4
34.8
97
250
N06AB04
ATC
citalopram; systemic
3.0
34.6
211
902
Z2445
NOMESCO Finland
Psychologist
6.4
34.5
60
102
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
14.0
34.2
32
24
L28
ICPC
Limited function/disability (L)
3.0
34.1
204
862
N04BX04
ATC
opicapone; oral
78.5
33.2
37
5
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
11.5
33.1
35
32
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.1
32.9
174
684
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.1
32.8
176
698
R5110, ,
SPAT
3.8
32.7
115
350
XKD00
NOMESCO Finland
Uroflowmetry
3.4
32.6
142
497
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.7
32.4
118
368
N28
ICPC
Limited function/disability (N)
10.0
31.8
37
39
G02CB01
ATC
bromocriptine; systemic
9.8
31.2
37
40
TAB00
NOMESCO Finland
Lumbar puncture
5.0
31.1
71
155
N06DA03
ATC
rivastigmine; oral, transdermal
4.9
30.5
72
162
SPAT1231
SPAT
Assessment of adjustments needed in living environment
9.1
30.4
38
44
N04BC02
ATC
pergolide; oral
316.5
30.1
30
*
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
33.5
29.4
38
12
L04AX07
ATC
dimethyl fumarate; oral
69.4
29.2
33
5
R1250
NOMESCO Finland
Evaluation of functional capability
6.5
28.9
49
81
R35
ICD-10 Finland
Polyuria
4.0
28.6
88
243
N06AX16
ATC
venlafaxine; oral
3.1
28.4
147
567
G04BD11
ATC
fesoterodine; oral
6.9
27.1
43
66
N29
ICPC
Neurological sympt/complt other
8.1
27.0
37
48
A28
ICPC
Limited function/disability NOS
2.7
26.9
183
815
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.7
26.7
94
285
A06AD11
ATC
lactulose; oral
2.9
26.4
156
645
XKD03
NOMESCO Finland
Urethral pressure profilometry
6.4
24.8
42
69
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
23.0
24.6
35
16
N03AX16
ATC
[U] pregabalin
2.5
24.4
209
1035
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.4
24.0
41
68
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.6
24.0
86
263
N05AH04
ATC
quetiapine; oral
2.7
23.5
159
702
N02BF01
ATC
gabapentin; oral
3.1
23.2
111
406
R33
ICD-10 Finland
Retention of urine
3.5
23.1
87
275
R4130
NOMESCO Finland
Speech therapy
5.8
23.0
43
78
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.9
22.6
72
203
N30.9
ICD-10 Finland
Cystitis, unspecified
3.6
22.5
81
248
N07XX09
ATC
[U] dimethyl fumarate
64.9
22.0
25
*
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.3
21.6
264
1512
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.9
21.4
68
191
N19
ICPC
Speech disorder
9.3
21.3
26
29
SPAT1216
SPAT
Assessment of functional ability
2.6
21.1
145
642
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
62.2
21.0
24
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.3
20.9
230
1258
TKC20
NOMESCO Finland
Catheterisation of bladder
3.6
20.9
74
224
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.3
20.7
85
283
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.9
20.6
112
439
A06AC01
ATC
ispaghula (psylla seeds); oral
2.3
20.3
229
1263
N05CF01
ATC
zopiclone; oral
2.2
20.1
274
1630
U04
ICPC
Incontinence urine
3.6
20.0
71
215
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.4
19.9
78
252
N06AA09
ATC
amitriptyline; systemic
2.9
19.8
101
382
D21
ICPC
Swallowing problem
7.1
19.7
30
44
N06AX11
ATC
mirtazapine; oral
2.2
19.6
273
1632
S72.0
ICD-10 Finland
Fracture of neck of femur
4.2
19.2
53
134
N30.0
ICD-10 Finland
Acute cystitis
2.5
19.2
154
730
R25.1
ICD-10 Finland
Tremor, unspecified
5.0
19.2
42
88
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
6.8
18.9
30
46
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.6
18.8
134
601
N05BA01
ATC
diazepam; systemic, rectal
2.6
18.5
122
527
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.8
18.0
98
383
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.4
17.9
159
787
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.6
17.6
62
187
N05BA04
ATC
oxazepam; oral
2.2
17.5
216
1222
J01MA02
ATC
ciprofloxacin; systemic
2.0
17.2
290
1840
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
65.1
16.8
19
*
U13
ICPC
Bladder symptom/complaint other
4.9
16.8
38
82
L04AE01
ATC
fingolimod; oral
+∞
16.7
16
*
N39.4
ICD-10 Finland
Other specified urinary incontinence
2.7
16.7
99
404
N04BC01
ATC
bromocriptine; oral
174.3
16.6
17
*
Z3226
NOMESCO Finland
Physiotherapist
2.3
16.0
150
756
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
5.9
16.0
29
51
R1260
NOMESCO Finland
Evaluation of communicative skills
6.1
15.8
28
48
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
61.6
15.8
18
*
C07AA05
ATC
propranolol; systemic
2.2
15.8
165
869
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
87.2
15.6
17
*
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
5.1
15.4
33
68
N03AF01
ATC
carbamazepine; oral, rectal
3.4
15.3
57
178
H02AA02
ATC
fludrocortisone; oral
14.4
15.1
25
18
XCK00
NOMESCO Finland
Perimetry
3.2
15.1
63
211
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.4
14.9
116
538
2AB04, ,
NOMESCO Finland
32.6
14.9
19
6
N04BC06
ATC
cabergoline; oral
25.7
14.8
20
8
TKC22
NOMESCO Finland
Catheterisation instruction
5.4
14.5
29
56
J01CA08
ATC
pivmecillinam; oral
1.9
14.4
316
2155
H02AB04
ATC
methylprednisolone; systemic
2.3
14.4
123
593
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.9
14.4
71
262
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
10.8
14.3
27
26
AA1AD
NOMESCO Finland
CT of head and brain
2.0
14.1
221
1347
M03BX02
ATC
tizanidine; oral
1.9
13.9
421
3177
L04AK02
ATC
teriflunomide; oral
54.6
13.9
16
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.2
13.8
149
790
K59.0
ICD-10 Finland
Constipation
3.2
13.7
58
196
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
4.3
13.6
36
88
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
11.3
13.6
25
23
N04BX01
ATC
tolcapone; oral
+∞
13.6
13
*
N04BC07
ATC
apomorphine; parenteral
+∞
13.6
13
*
34099
ICD-8 Finland
Multiple sclerosis
142.9
13.5
14
*
N05CD07
ATC
temazepam; oral
2.4
13.4
106
494
NFB20
NOMESCO Finland
Primary partial prosthetic replacement of hip joint using cement, other or unspecified
4.6
13.2
32
73
XF606
NOMESCO Finland
Ortostatic test
15.5
13.2
21
14
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
6.3
13.0
22
36
N06AB10
ATC
escitalopram; oral
2.1
12.7
154
852
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
6.1
12.7
22
37
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
71.3
12.6
14
*
H02AB07
ATC
prednisone; oral
2.3
12.6
112
548
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
14.7
12.3
20
14
I95.1
ICD-10 Finland
Orthostatic hypotension
3.6
12.3
41
119
U02
ICPC
Urinary frequency/urgency
2.1
11.9
125
653
L04AG12
ATC
ofatumumab; parenteral
+∞
11.5
11
*
4AA23, ,
NOMESCO Finland
122.1
11.5
12
*
G04AC01, ,
ATC
3.8
11.4
35
96
359
Kela drug reimbursment
Mirabegroni
15.4
11.4
18
12
J01XE01
ATC
nitrofurantoin; oral
4.7
11.3
26
57
R5130, ,
SPAT
25.5
11.2
15
6
J01MA06
ATC
norfloxacin; oral
2.1
11.1
112
576
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
4.5
11.1
27
62
N06AX18
ATC
reboxetine; oral
10.3
11.1
21
21
W19
ICD-10 Finland
Unspecified fall
2.4
11.0
83
377
N06AX21
ATC
duloxetine; oral
2.2
11.0
99
485
R53
ICD-10 Finland
Malaise and fatigue
1.9
11.0
190
1178
H53.2
ICD-10 Finland
Diplopia
3.6
11.0
37
108
R4110, ,
SPAT
2.1
10.9
111
572
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.1
10.9
116
608
ZX120
NOMESCO Finland
Intravenous
2.4
10.9
76
334
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.3
10.9
88
413
SPAT1262
SPAT
Handing over of treatment supplies
2.1
10.9
125
675
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
10.3
10.6
20
20
M41.9
ICD-10 Finland
Scoliosis, unspecified
5.5
10.5
20
37
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
111.8
10.4
11
*
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
10.4
10
*
L89
ICD-10 Finland
Decubitus ulcer and pressure area
4.5
10.3
25
57
R4110
NOMESCO Finland
Physiotherapy
1.8
10.3
197
1258
H47.2
ICD-10 Finland
Optic atrophy
23.8
10.3
14
6
S97
ICPC
Chronic ulcer skin
2.6
10.3
61
248
J01MA01
ATC
ofloxacin; systemic
2.4
10.3
72
317
U07
ICPC
Urine symptom/complaint other
2.4
10.2
73
324
L04AX01
ATC
azathioprine; systemic
3.4
10.1
36
109
Z43.5
ICD-10 Finland
Attention to cystostomy
14.9
10.0
16
11
Z93.5
ICD-10 Finland
Cystostomy status
40.7
10.0
12
*
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.3
10.0
83
394
Z3231
NOMESCO Finland
Registered nurse
1.8
9.9
188
1195
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
2.8
9.8
52
199
N03AF02
ATC
oxcarbazepine; oral
3.5
9.7
33
97
J01XX05
ATC
methenamine; oral
8.0
9.7
21
27
AAW01
NOMESCO Finland
Implantation of intracranial stimulation device
55.8
9.7
11
*
A07DA03
ATC
loperamide; oral
3.5
9.6
33
98
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
1.8
9.6
180
1140
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
15.3
9.5
15
10
U71
ICPC
Cystitis/urinary infection other
2.5
9.5
61
257
K03.66
ICD-10 Finland
Tooth plaque
2.5
9.5
60
251
K59.09
ICD-10 Finland
Constipation, unspecified
2.5
9.4
60
252
L03AB13
ATC
peginterferon beta-1a; parenteral
101.5
9.4
10
*
SPAT1167
SPAT
Insertion of urinary catheter
3.9
9.4
28
75
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
22.1
9.4
13
6
S01.0
ICD-10 Finland
Open wound of scalp
2.4
9.3
68
305
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.1
9.2
96
499
N05BA12
ATC
alprazolam; oral
2.2
9.1
77
367
G04CA02
ATC
tamsulosin; oral
1.9
9.0
140
834
N99
ICPC
Neurological disease other
7.6
9.0
20
27
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
2.8
9.0
44
162
G04BDXX, ,
ATC
24.4
8.9
12
5
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.1
8.9
87
441
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
2.4
8.6
63
282
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
2.5
8.6
53
219
N07AA03
ATC
distigmine; systemic
27.9
8.5
11
*
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
27.9
8.5
11
*
M48.0
ICD-10 Finland
Spinal stenosis
2.0
8.5
96
513
N06AX12
ATC
bupropion; oral
2.6
8.4
50
203
U08
ICPC
Urinary retention
4.7
8.4
19
41
N03AX09
ATC
lamotrigine; oral
2.9
8.4
40
145
N04AA01
ATC
trihexyphenidyl; oral
+∞
8.3
8
*
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
10.9
8.3
15
14
R1250, ,
SPAT
3.3
8.3
31
97
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.0
8.3
36
124
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
4.1
8.1
22
55
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
6.4
8.1
20
32
R4130, ,
SPAT
22.3
8.0
11
5
R4120
NOMESCO Finland
Occupational therapy
2.5
8.0
53
227
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.0
7.9
94
510
N05AB04
ATC
prochlorperazine; systemic, rectal
4.0
7.9
22
56
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
7.9
7.9
17
22
A02BA02
ATC
ranitidine; systemic
1.8
7.9
139
859
Z01.8
ICD-10 Finland
Other specified special examinations
1.8
7.9
151
956
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
15.2
7.7
12
8
XF400
NOMESCO Finland
ECG with 12 standard connections
1.9
7.7
108
620
X59
ICD-10 Finland
Exposure to unspecified factor
1.8
7.7
126
760
Z3229
NOMESCO Finland
Other healthcare associate professional
2.2
7.6
62
292
N02AA05
ATC
oxycodone; systemic
1.8
7.5
134
829
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
4.5
7.5
18
41
K02.1
ICD-10 Finland
Caries of dentine
1.6
7.4
358
2844
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
81.0
7.4
8
*
3419X
ICD-9 Finland
Other demyelinating diseases of central nervous system, Demyelinating disease of central nervous system, unspecified
+∞
7.3
7
*
AA5QN, ,
NOMESCO Finland
+∞
7.3
7
*
OAB50, ,
SPAT
2.2
7.3
60
283
ZXM10
NOMESCO Finland
Intraoperative use of conventional X-ray imaging
2.3
7.3
53
237
N02AX02
ATC
tramadol; systemic, rectal
1.6
7.2
282
2132
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
1.9
7.2
103
596
U05
ICPC
Urination problems other
2.5
7.2
43
176
G04BD
ATC
Drugs for urinary frequency and incontinence
20.3
7.1
10
5
N05CF02
ATC
zolpidem; oral
1.8
7.1
124
761
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.6
7.1
239
1744
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
4.3
7.0
18
43
ABC26
NOMESCO Finland
Open discectomy of lumbar spine
4.3
7.0
18
43
H53.1
ICD-10 Finland
Subjective visual disturbances
2.3
7.0
52
235
SFA20
NOMESCO Finland
Two-surface restoration
1.5
6.8
358
2879
N02AC04
ATC
dextropropoxyphene; oral
2.9
6.8
31
110
36703
ICD-8 Finland
Inflammation of optic nerve and retina, Neuritis optica, retrobulbaris
40.5
6.8
8
*
G23.9
ICD-10 Finland
Degenerative disease of basal ganglia, unspecified
40.5
6.8
8
*
R32
ICD-10 Finland
Unspecified urinary incontinence
3.1
6.7
28
94
SPAT1301
SPAT
No procedures
1.6
6.7
196
1380
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
2.7
6.6
36
140
WX110
NOMESCO Finland
Infiltration anesthesia
1.6
6.6
440
3715
NE1AA
NOMESCO Finland
Pelvis X-ray examination
2.1
6.6
62
309
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
8.8
6.6
13
15
SPAT1172
SPAT
Guidance concerning hydration
3.7
6.5
20
55
EB1SA
NOMESCO Finland
Dental X-ray, bite-wing X-ray on one side of the mouth
1.5
6.5
281
2157
L04AA40
ATC
cladribine; oral
70.5
6.4
7
*
ZXH01
NOMESCO Finland
Procedure performed within operation theatre
70.5
6.4
7
*
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
2.9
6.4
30
108
WZC00
NOMESCO Finland
Treatment plan or consultation
1.6
6.4
228
1676
M01AG02
ATC
tolfenamic acid; oral, rectal
1.8
6.4
106
641
A04
ICPC
Weakness/tiredness general
1.8
6.3
104
627
N06AB06
ATC
sertraline; oral
1.9
6.3
79
437
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
2.2
6.3
50
233
SPAT1360
SPAT
Extensive global examination
2.3
6.3
46
207
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
7.1
6.2
14
20
A02BC02
ATC
pantoprazole; systemic
1.6
6.2
443
3770
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
1.8
6.2
89
514
ND1BA
NOMESCO Finland
Wrist extensive X-ray examination
3.5
6.2
21
62
K08.3
ICD-10 Finland
Retained dental root
2.2
6.2
52
248
R06AE07
ATC
cetirizine; oral
1.5
6.2
269
2063
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
7.8
6.1
13
17
OAB43, ,
SPAT
0.5
6.1
67
1175
3AX01, ,
NOMESCO Finland
10.1
6.0
11
11
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
10.1
6.0
11
11
M43.1
ICD-10 Finland
Spondylolisthesis
2.6
6.0
35
141
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
5.6
6.0
16
29
SPAT1312
SPAT
General health counselling
1.6
6.0
185
1312
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
51
70
7.82
35.67
1.2
1.2
—
—
—
0
0
34
35
10.20
29.67
4.8
1.6
477.66
531.46
e6/l
0.29
29
28
30
26
12.05
29.33
1.8
1.3
61.93
98.22
nmol/l
0.67
15
17
33
6
57.81
28.41
2.2
3.7
—
—
—
0
0
283
1618
2.33
23.80
5.2
3.1
0.28
0.41
e6/l
0.95
221
1184
313
1886
2.28
23.02
5.6
3.3
38.95
51.66
e6/l
0.27
251
1448
234
1315
2.22
19.69
4.3
2.6
5.73
6.00
e6/l
0.09
213
1199
27
35
8.01
19.68
1.1
1.0
—
—
—
0
0
331
2136
2.13
19.46
6.7
3.9
119.46
81.23
e6/l
0.54
262
1513
25
31
8.35
18.88
1.4
1.1
1.01
0.51
ratio
—
10
16
28
41
7.09
18.38
1.0
1.1
49.95
41.34
mg/l
0.33
17
34
22
6
37.88
17.71
1.1
1.0
—
—
—
0
0
110
462
2.66
17.56
4.6
2.6
9.24
10.66
g/l
3.70
98
422
25
39
6.63
15.47
2.4
1.8
—
—
—
0
0
58
182
3.40
15.44
1.7
1.6
70.09
0.12
iu/ml
—
5
28
428
3222
1.97
14.53
11.4
9.7
4.08
4.12
e9/l
0.14
390
2815
475
3712
2.05
14.43
10.3
4.9
466.50
2834.26
e6/l
—
10
66
364
2625
1.88
13.75
2.7
2.5
90.18
78.39
nmol/l
8.32
326
2368
165
919
2.07
13.42
4.7
3.0
4.34
2.76
e6/l
0.70
88
445
408
3070
1.89
13.30
7.1
4.0
0.00
0.52
estimate
0.52
96
594
405
3045
1.88
13.18
7.1
4.0
0.00
2.55
estimate
0.50
102
636
401
3018
1.86
12.87
7.1
3.9
0.00
0.00
estimate
0.50
100
621
169
997
1.94
11.48
4.6
2.9
1.24
1.02
e6/l
0.48
95
524
26
61
4.40
10.39
1.0
1.1
—
—
—
0
0
335
2487
1.72
10.30
16.5
11.2
0.00
0.00
e9/l
0.58
290
2033
26
63
4.26
9.98
1.0
1.1
—
—
—
0
0
27
70
3.98
9.49
2.1
2.6
1.19
1.19
mmol/l
0.08
27
70
27
71
3.92
9.31
2.1
2.6
106.85
105.80
mmol/l
0.42
27
71
27
71
3.92
9.31
2.1
2.6
4.07
4.04
mmol/l
0.14
27
71
237
1659
1.68
8.66
7.3
3.3
0.03
0.07
estimate
0.29
93
491
252
1801
1.65
8.45
2.5
2.1
170.83
188.73
u/l
0.26
238
1705
37
128
3.01
8.42
1.1
1.2
5.04
17.31
e6/l
0.85
26
91
40
145
2.87
8.38
3.2
1.9
12532.02
1602.35
u/l
0.47
13
50
22
54
4.18
8.32
1.0
1.0
—
—
—
0
0
152
952
1.78
8.24
1.9
2.0
—
—
—
0
0
37
130
2.96
8.20
1.2
1.2
68.65
138.06
e6/l
0.52
26
95
18
27
6.82
7.63
1.2
1.0
2220.33
1649.93
miu/ml
0.95
18
27
365
2912
1.58
7.44
6.2
6.9
1.22
1.21
mmol/l
0.24
316
2521
452
5116
0.61
7.09
4.1
4.3
1.22
1.28
mmol/l
1.13
402
4694
297
2310
1.53
6.45
7.5
3.8
0.05
0.04
estimate
0.03
85
507
482
5341
0.62
6.26
4.8
5.1
1.50
1.49
mmol/l
0.13
428
4940
321
2563
1.50
6.01
3.7
4.8
35.64
35.64
g/l
0.00
294
2401
17
34
5.11
5.91
1.0
1.1
1.16
1.14
u/l
—
8
17
487
5361
0.63
5.70
4.8
5.2
4.60
4.67
mmol/l
0.74
434
4983
321
2585
1.48
5.64
2.5
2.1
93.78
96.60
pmol/l
0.50
186
1331
229
1729
1.50
5.51
2.1
1.7
21.99
20.41
nmol/l
0.75
191
1453
499
5450
0.63
5.37
5.3
6.0
2.64
2.71
mmol/l
1.00
443
5054
324
2636
1.46
5.27
6.3
6.1
1.22
1.21
mmol/l
0.38
300
2429
33
140
2.43
5.15
1.2
1.2
—
—
—
0
0
488
4318
1.53
5.08
7.5
8.2
81.16
79.00
u/l
0.43
453
4089
225
1717
1.48
5.04
7.8
4.0
0.07
0.01
estimate
0.44
91
585
144
1000
1.57
5.03
1.8
1.7
996.62
1208.93
nmol/l
2.19
105
738
63
350
1.89
4.97
1.8
1.8
—
—
—
0
0
53
281
1.97
4.80
5.8
3.6
1.02
1.02
ratio
1.04
45
264
109
718
1.62
4.74
1.9
1.9
—
—
—
0
0
390
3339
1.42
4.51
5.7
4.8
6.38
6.67
mmol/l
2.34
378
3162
41
204
2.08
4.43
1.8
1.9
—
—
—
0
0
39
191
2.11
4.39
1.7
1.7
—
—
—
0
0
55
309
1.85
4.21
1.4
1.5
—
—
—
0
0
79
497
1.67
4.11
3.9
2.5
0.43
0.58
e6/l
0.23
79
472
100
682
1.55
3.74
1.9
2.0
—
—
—
0
0
355
3047
1.37
3.72
5.0
6.5
9.60
11.06
umol/l
3.60
335
2915
150
1941
0.70
3.47
3.4
3.3
7.54
7.32
mmol/l
0.24
122
1627
7
11
6.42
3.19
1.6
2.0
14.06
19.57
umol/l
—
7
11
10
27
3.74
2.89
3.1
2.2
—
—
—
0
0
174
1384
1.35
2.83
2.2
2.3
—
—
—
0
0
459
4181
1.34
2.82
4.1
4.4
10.99
12.35
mm/h
1.57
414
3896
11
33
3.37
2.82
1.6
1.8
33.50
36.12
mg/l
—
6
25
83
581
1.49
2.77
4.9
3.3
—
—
—
0
0
304
2625
1.30
2.74
2.7
2.7
—
—
estimate
—
0
0
27
142
1.94
2.59
2.1
3.2
2.60
1.86
index
—
10
78
56
365
1.58
2.58
1.4
1.3
—
50.70
—
0
34
51
325
1.62
2.58
3.3
3.4
2.07
2.00
mmol/l
0.07
46
246
118
897
1.39
2.53
1.9
2.4
2.43
2.31
g/l
1.29
103
834
10
31
3.26
2.52
1.1
1.4
—
—
—
0
0
9
27
3.37
2.40
1.8
1.7
61.16
52.59
ug/l
—
9
27
26
139
1.91
2.40
1.5
1.7
—
—
—
0
0
11
261
0.41
2.35
1.1
1.3
—
—
—
0
0
124
963
1.36
2.33
2.0
2.4
12.30
12.98
umol/l
0.44
107
899
260
2236
1.27
2.31
5.1
3.9
30.55
76.65
ng/l
0.92
214
1620
27
465
0.56
2.29
2.2
2.7
64.63
63.27
ml/min/173m2
—
8
219
156
1901
0.76
2.26
4.3
4.1
4.48
8.41
mg/mmol
2.50
104
1159
47
309
1.56
2.13
8.0
2.3
0.71
0.61
%
1.78
47
309
107
830
1.35
2.03
1.9
2.4
20.32
22.38
%
0.81
93
783
42
625
0.65
1.99
3.8
4.5
3.99
30.01
ug/l
1.28
36
520
63
456
1.42
1.82
3.3
3.9
1.23
1.23
mmol/l
0.18
54
398
73
956
0.73
1.73
1.8
1.5
—
—
—
0
0
26
156
1.69
1.71
2.0
1.9
7.01
4.10
iu/l
—
8
59
12
55
2.20
1.68
2.3
2.4
—
—
—
0
0
205
2346
0.82
1.64
1.9
1.9
1.28
1.33
mmol/l
0.49
160
1971
19
107
1.80
1.56
1.3
1.4
—
—
—
0
0
19
107
1.80
1.56
1.3
1.4
—
—
—
0
0
10
44
2.29
1.56
1.3
1.8
—
—
—
0
0
501
5245
0.80
1.54
4.7
5.2
5.72
5.94
mmol/l
5.34
450
4818
560
5379
1.31
1.53
22.3
16.2
25.88
23.71
mg/l
0.73
485
4431
0
43
0.00
1.52
0.0
2.5
—
695.05
—
0
43
177
1521
1.23
1.49
2.9
2.2
3.33
2.97
mg/l
0.73
151
1308
10
45
2.24
1.47
1.0
1.1
134.60
106.36
pmol/l
—
10
45
462
4358
1.21
1.40
5.1
4.5
15.04
14.77
pmol/l
1.39
423
4008
55
410
1.37
1.38
1.9
1.6
—
—
—
0
0
5
17
2.96
1.36
1.6
2.4
0.65
0.61
mmol/l
—
5
17
92
1124
0.79
1.32
4.5
4.6
20.87
21.72
%
0.28
48
540
94
1142
0.79
1.29
1.5
1.3
16.86
32.84
iu/ml
2.18
16
358
571
5528
1.28
1.23
23.8
19.2
3.93
3.97
mmol/l
3.53
562
5402
67
841
0.77
1.20
3.6
3.2
0.66
0.77
ug/l
0.90
45
547
9
169
0.53
1.20
1.4
1.2
—
—
—
0
0
12
64
1.89
1.18
2.0
2.0
88.04
89.64
%
0.35
12
64
529
5086
1.22
1.17
6.5
5.6
1.79
1.93
mu/l
1.99
495
4701
69
548
1.29
1.16
7.5
3.2
2.67
1.97
mmol/l
1.30
60
464
143
1234
1.20
1.15
1.8
1.7
431.70
33301126.10
pmol/l
1.43
119
1021
216
1934
1.18
1.14
3.6
3.0
28.40
30.43
u/l
0.55
208
1825
569
5519
1.26
1.11
24.0
19.0
139.97
139.67
mmol/l
2.15
563
5404
152
1324
1.19
1.11
1.4
1.3
0.79
1.56
u/ml
1.22
31
361
5
21
2.39
1.09
1.4
2.0
42.74
42.63
g/l
—
5
21
7
33
2.13
1.06
1.1
1.8
79.03
91.89
ng/l
—
7
33
58
457
1.30
1.05
3.1
3.4
76.02
81.24
ng/l
0.33
42
396
104
880
1.22
1.03
2.4
1.8
29.00
29.46
s
0.49
99
855
497
5156
0.84
1.03
5.9
6.5
38.25
39.37
mmol/mol
2.33
446
4841
87
725
1.23
1.00
3.6
5.0
1.02
1.03
mmol/l
0.05
73
657
7
35
2.01
1.00
1.1
1.5
3.14
2.92
u/field
—
7
26
7
35
2.01
1.00
1.6
1.5
6.14
8.85
u/l
—
7
28
9
160
0.56
0.99
1.1
1.1
—
—
—
0
0
349
3269
1.15
0.97
3.1
3.0
—
—
—
0
0
203
1831
1.16
0.96
2.4
2.5
49.68
62.09
u/l
2.70
188
1706
110
946
1.20
0.93
1.5
1.5
—
—
—
0
0
538
5210
1.19
0.93
20.5
15.8
85.59
79.68
ml/min/173m2
10.19
505
4826
6
28
2.15
0.91
2.0
3.9
219.17
652.46
u/ml
—
6
28
391
3707
1.14
0.87
4.0
3.3
46.38
47.34
u/l
0.07
354
3495
28
204
1.39
0.86
1.5
2.5
0.08
1.01
g/l
2.20
23
182
12
73
1.66
0.82
3.5
9.1
5.88
6.94
mmol/l
1.49
12
60
15
97
1.56
0.82
1.3
1.4
—
—
—
0
0
33
251
1.33
0.80
1.6
2.0
1.48
1.48
g/l
0.01
27
224
0
24
0.00
0.79
0.0
3.4
—
199.17
—
0
24
0
25
0.00
0.79
0.0
1.2
—
9.60
—
0
25
5
97
0.51
0.78
1.0
1.4
—
166.05
—
0
28
0
27
0.00
0.77
0.0
1.3
—
—
—
0
0
6
34
1.77
0.76
1.5
1.7
—
—
—
0
0
10
161
0.62
0.76
1.1
1.1
—
—
—
0
0
71
600
1.21
0.74
2.3
1.9
346.09
383.65
nmol/l
0.93
64
559
137
1226
1.15
0.73
2.3
2.8
2.46
2.45
mmol/l
0.17
124
1101
5
25
2.01
0.73
1.2
1.3
—
—
—
0
0
22
160
1.39
0.71
2.1
1.5
—
—
—
0
0
5
27
1.86
0.68
1.0
1.1
—
—
—
0
0
14
203
0.68
0.68
2.2
2.9
—
—
—
0
0
196
1806
1.12
0.67
2.8
3.3
917.98
1264.91
ng/l
1.75
173
1541
5
29
1.73
0.64
1.6
1.8
—
—
—
0
0
17
121
1.42
0.63
1.9
2.7
6.16
8.24
pmol/l
0.92
17
121
223
2077
1.11
0.63
2.5
3.5
2.35
2.36
mmol/l
0.26
196
1882
5
30
1.67
0.61
1.6
1.8
—
—
—
0
0
5
30
1.67
0.61
1.8
1.7
—
—
—
0
0
5
30
1.67
0.61
1.8
1.7
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
40.97
—
0
21
92
1037
0.87
0.60
1.4
1.3
1.08
10.04
u/ml
4.95
29
406
21
161
1.31
0.52
1.3
1.6
—
—
—
0
0
6
98
0.61
0.52
1.0
2.6
—
979.63
—
0
8
9
135
0.66
0.52
1.2
1.4
—
—
—
0
0
13
180
0.72
0.52
2.7
3.3
4.28
2.26
ratio
—
7
104
9
64
1.41
0.51
1.0
1.2
—
70.43
—
0
7
16
118
1.36
0.50
1.4
1.6
—
—
—
0
0
21
163
1.30
0.49
1.2
1.6
—
—
—
0
0
11
76
1.46
0.48
1.5
1.6
—
—
—
0
0
12
166
0.72
0.48
2.3
2.5
12.03
12.63
mg/l
0.07
12
153
10
68
1.48
0.47
1.1
1.3
—
—
—
0
0
132
1430
0.90
0.46
1.9
2.6
297.18
337.14
umol/l
4.68
113
1263
145
1343
1.10
0.46
6.7
4.1
1.02
1.02
kg/l
0.05
114
907
80
716
1.13
0.46
4.5
4.9
32.43
31.86
%
0.17
53
468
61
537
1.15
0.44
2.0
2.4
28.04
32.75
u/l
0.89
48
447
13
95
1.38
0.44
1.5
1.6
—
—
—
0
0
14
185
0.75
0.43
1.0
1.2
1.66
1.58
g/l
0.57
14
185
11
78
1.42
0.43
1.3
1.6
—
—
—
0
0
283
2707
1.08
0.43
3.2
3.0
117.21
117.34
ug/l
0.00
260
2524
0
16
0.00
0.41
0.0
1.3
—
7.80
—
0
6
54
612
0.87
0.41
1.5
1.7
1.42
1.45
%
0.23
48
527
0
17
0.00
0.40
0.0
1.0
—
—
—
0
0
5
34
1.47
0.40
1.2
1.5
69.80
76.44
umol/l
—
5
34
5
34
1.47
0.40
1.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
22
180
1.23
0.36
1.6
1.4
342.06
302.55
ug/g
0.37
14
107
15
190
0.78
0.36
1.0
1.2
0.78
0.91
g/l
2.05
15
190
118
1097
1.09
0.36
4.7
4.0
104.97
364.30
ng/l
2.09
91
855
41
360
1.15
0.33
2.2
2.5
15.94
13.05
nmol/l
1.02
36
327
17
138
1.24
0.30
1.4
1.5
—
—
—
0
0
23
195
1.19
0.28
1.5
1.6
—
—
—
0
0
13
103
1.27
0.28
1.5
1.8
—
—
—
0
0
11
139
0.79
0.27
1.5
1.9
42.64
41.45
nmol/l
0.08
11
134
10
77
1.30
0.26
1.1
1.3
—
—
—
0
0
53
484
1.10
0.25
1.8
2.9
66.94
66.98
g/l
0.02
42
448
9
76
1.19
0.24
1.1
1.3
—
—
—
0
0
9
76
1.19
0.24
1.1
1.3
—
—
—
0
0
9
77
1.17
0.24
1.1
1.3
—
—
—
0
0
25
218
1.15
0.23
1.4
1.8
—
—
—
0
0
10
79
1.27
0.22
1.1
1.3
—
—
—
0
0
10
79
1.27
0.22
1.1
1.3
—
—
—
0
0
5
41
1.22
0.22
1.2
1.0
—
—
—
0
0
19
163
1.17
0.21
1.7
1.5
71.37
210.24
pmol/l
1.13
19
158
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
39.00
—
0
6
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
2.78
—
0
5
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
17
145
1.18
0.20
1.3
1.3
—
—
—
0
0
57
530
1.08
0.19
9.1
6.7
1.36
1.31
mmol/l
0.16
57
517
23
260
0.88
0.19
1.1
1.0
—
—
—
0
0
103
981
1.06
0.19
2.8
3.1
0.83
0.82
mmol/l
0.27
92
927
44
477
0.92
0.19
2.0
1.9
—
—
—
0
0
5
66
0.76
0.17
1.2
1.7
—
—
—
0
0
5
69
0.72
0.17
1.0
1.0
—
—
—
0
0
578
5818
0.94
0.16
35.3
25.1
39.59
40.03
%
1.06
573
5751
578
5818
0.94
0.16
34.6
24.6
4.38
4.44
e12/l
2.29
566
5692
8
70
1.14
0.16
3.1
4.0
22.21
62.31
u/ml
—
8
70
578
5817
0.94
0.16
34.6
24.7
260.12
251.93
e9/l
2.50
569
5712
21
187
1.13
0.16
1.2
1.3
—
—
—
0
0
62
656
0.94
0.15
5.5
7.0
—
—
—
0
0
578
5816
0.94
0.15
34.5
24.6
91.86
91.27
fl
2.82
573
5753
44
471
0.93
0.15
2.1
2.4
4.42
6.96
ug/l
1.27
35
415
137
1414
0.96
0.14
5.6
5.5
2.34
2.39
ug/l
0.04
118
1260
21
192
1.10
0.11
1.4
1.4
—
—
—
0
0
69
663
1.05
0.10
2.1
2.5
8.40
7.59
umol/l
0.19
60
587
5
44
1.14
0.10
1.8
1.1
—
—
—
0
0
5
44
1.14
0.10
1.0
1.2
1.43
2.96
ug/l
—
5
35
5
45
1.11
0.10
1.8
1.1
—
—
—
0
0
5
47
1.06
0.09
1.8
1.1
—
—
—
0
0
5
47
1.06
0.09
1.8
1.1
—
—
—
0
0
20
184
1.09
0.09
1.2
1.3
—
—
—
0
0
5
60
0.83
0.08
1.2
1.8
—
—
—
0
0
5
60
0.83
0.08
1.8
1.2
—
—
—
0
0
6
72
0.83
0.07
5.3
4.0
—
—
—
0
0
7
83
0.84
0.07
1.6
1.5
—
—
—
0
0
13
118
1.10
0.07
1.4
1.5
—
—
—
0
0
43
413
1.04
0.07
1.3
1.2
54.12
155.60
u/ml
4.00
17
166
133
1306
1.02
0.06
2.1
1.7
1.21
1.25
mg/l
0.07
109
1033
15
138
1.09
0.06
1.7
1.5
—
—
—
0
0
17
182
0.93
0.05
1.2
1.2
—
2.59
—
0
21
66
676
0.97
0.05
4.6
7.2
12.07
12.15
kpa
0.05
61
654
42
434
0.97
0.05
2.0
1.8
—
—
—
0
0
68
666
1.02
0.04
4.4
7.3
0.25
1.12
mmol/l
0.77
53
553
14
149
0.94
0.03
1.1
1.2
—
8.60
—
0
10
567
5657
1.02
0.03
15.4
12.3
22.04
24.91
u/l
5.49
540
5497
21
218
0.96
0.02
1.8
2.0
2.89
4.19
mg/l
0.35
16
166
45
459
0.98
0.02
1.6
1.5
—
—
—
0
0
17
167
1.02
0.00
1.7
1.7
—
—
—
0
0
22
217
1.01
0.00
1.5
1.6
—
—
—
0
0
16
162
0.99
0.00
1.1
1.2
—
—
—
0
0
23
228
1.01
0.00
1.3
1.4
0.32
0.30
mg/l
—
10
97
27
268
1.01
0.00
1.5
1.9
—
—
—
0
0
7
79
0.88
-0.00
1.1
1.1
—
—
—
0
0
5
49
1.02
-0.00
1.2
1.3
891242.00
395326.84
e6/l
—
5
32
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
7
69
1.01
-0.00
1.0
1.1
1.31
1.46
g/l
—
7
62
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
1.19
—
0
8
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
8.8
—
10.51
—
0
8
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
8.0
—
5.87
—
0
9
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
15
150
1.00
-0.00
1.1
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.03
—
0
5
5
51
0.98
-0.00
1.8
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
6.34
—
0
8
5
57
0.88
-0.00
1.2
1.1
102.00
100.54
%
—
5
52
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
5
52
0.96
-0.00
1.2
1.6
—
371.25
—
0
8
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_AMANTADINE – Use of amantadine
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).